Tes HPV DNA Lebih Direkomendasikan untuk Skrining Kanker Serviks

Oleh :

Josephine Darmawan

Tes HPV DNA mulai menjadi metode skrining yang lebih disarankan untuk skrining kanker serviks. Sudah banyak pedoman baru yang merekomendasikan skrining kanker serviks menggunakan tes HPV (Human Papilloma Virus) DNA setiap 5 tahun atau kombinasi dengan tes Pap smear setiap 5 tahun.

Pedoman baru ini sudah diberlakukan di berbagai negara, seperti Amerika Serikat dan Australia, karena tes HPV DNA dinilai dapat mengurangi jumlah paparan risiko akibat frekuensi tindakan, meningkatkan kepatuhan pasien terhadap jadwal skrining, dan lebih efisien secara waktu ataupun finansial.[1-5] Pedoman skrining baru ini juga dinilai dapat menekan insidensi kanker serviks hingga 30%.[1,2,6] Namun, masih belum diterapkan secara luas di Indonesia. [7]

Pentingnya Skrining Kanker Serviks

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. Adv Cerv Cancer Manag. 2014;52242:22–40.
2. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Cervical cancer screening in Australia. RANZOG. 2017.
3. Mandelblatt JS. Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer. JAMA, 2002. 287(18): 2372. doi:10.1001/jama.287.18.2372
4. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer, 2006. 119(5): 1095–1101. doi:10.1002/ijc.21955
5. Racey CS, Withrow DR, Gesink D. Self Collected HPV Testing Improves Participation in Cervical Cancer Screening: A Systematic Review and Metaanalysis. Can J Public Health, 2013. 104(2): 159-166. https://doi.org/10.1007/BF03405681
6. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. Cervical Cancer Screening Recommendations and Considerations. CDC. 2018. Diakses dari: https://www.cdc.gov/cancer/knowledge/provider-education/cervical/recommendations.htm
7. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Kanker Serviks. Kemenkes RI. 2015.
8. Pusat Data dan Informasi Kementrian Kesehatan RI. Situasi Penyakit Kanker. Kemenkes RI. 2014;1–5.
9. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. The Lancet, 2004. 364(9430): 249–256. doi:10.1016/s0140-6736(04)16674-9
10. Dickinson JA, Stankiewicz A, Popadiuk C, et al. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health, 2012. 12(1). doi:10.1186/1471-2458-12-992
11. Mastutik G, Alia R, Rahniayu A, Kurniasari N, Rahaju AS, Mustokoweni S. Skrining Kanker Serviks dengan Pemeriksaan Pap Smear di Puskesmas Tanah Kali Kedinding Surabaya dan Rumah Sakit Mawadah Mojokerto. Maj Obstet Ginekol. 2015;23:54.
12. Pankaj S, Nazneen S, Kumari S, Kumari A, Kumari A, Kumari J, et al. Comparison of conventional Pap smear and liquid-based cytology: A study of cervical cancer screening at a tertiary care center in Bihar. Vol. 55, Indian Journal of Cancer. 2018:80.
13. Karimi-Zarchi M, Peighmbari F, Karimi N, Rohi M, Chiti Z. A comparison of 3 ways of conventional pap smear, liquid-based cytology and colposcopy vs cervical biopsy for early diagnosis of premalignant lesions or cervical cancer in women with abnormal conventional Pap test. Vol. 9, International Journal of Biomedical Science. 2013:205–10.
14. Sinha P, Srivastava P, Srivastava A. Comparison of Visual Inspection with Acetic Acid and the Pap Smear for Cervical Cancer Screening. Acta Cytol. 2018;62:34–8.
15. Bhattacharyya A, Nath J, Deka H. Comparative study between pap smear and visual inspection with acetic acid (via) in screening of CIN and early cervical cancer. J Midlife Heal. 2015;6:53–8.
16. Sokkary HHAH El. Comparison between Pap Smear and Visual Inspection with Acetic Acid in Screening of Premalignant Cervical Intraepithelial Lesion and Subclinical Early Cancer Cervix. Int J Reprod Contraception, Obstet Gynecol. 2016;6:54.
17. Saleh HS. Can visual inspection with acetic acid be used as an alternative to Pap smear in screening cervical cancer? Middle East Fertil Soc J. 2014;19:187–91.
18. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO. 2013;60.
19. Gravitt PE, Paul P, Katki HA, et al. Effectiveness of VIA, Pap, and HPV DNA Testing in a Cervical Cancer Screening Program in a Peri-Urban Community in Andhra Pradesh, India. PLoS ONE, 2010. 5(10): e13711. doi:10.1371/journal.pone.0013711
20. Wikström I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. British Journal of Cancer, 2011. 105(3): 337–339.doi:10.1038/bjc.2011.236
21. Van Rosmalen J, de Kok I, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG: An International Journal of Obstetrics & Gynaecology, 2012. 119(6): 699–709. doi:10.1111/j.1471-0528.2011.03228.x
22. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. The Lancet Oncology, 2010. 11(3): 249–257.doi:10.1016/s1470-2045(09)70360-2